PPepDB-ID	"Peptide Name"	PMID	"Plant source"	"Plant Family"	"Peptide Family"	"Peptide function"	"Peptide function description"	"Activity against"	Sequence	"Sequence Length"	Validation	"Avg. Molecular wt(Da)"	"Monoisotopic molecular wt(Da)"	pI	Method	"Additional information"
PPepDB_2205	Ib-AMP4	"3713064, 23713064, 9305910, 9454588"	"Impatiens balsamina"	Balsaminaceae	"Impatiens family"	"Antibacterial, Hemolytic, Cytotoxic, Antifungal"	"plays a role in the defense of the germinating seed agasnst microorganisms by inhibiting the growth of a range of filamentous fungi and bacteria, especially Gram-positive bacteria, Target site: lipid bilayer; Not active up to 100 µg/ml against Sheep erythrocytes; shows 15% Hemolysis against Sheep erythrocytes at 200 µg/ml"	"Acinetobacter calcoAngiotensin Converting Enzymeticus (MIC: >128 µg/ml), Proteus vulgaris (MIC: 32-64 µg/ml), Proteus mirabilis (MIC: 32-128 µg/ml), Enterobacter cloacae (MIC: 4-8 µg/ml), Enterobacter aerogenes (MIC: 2-4 µg/ml), Serratia marcescens (MIC: 8-16 µg/ml), Serratia marcescens (MIC: 8-16 µg/ml), Pseudomonas aeruginosa (MIC: >128 µg/ml), Klebsiella oxytoca (MIC: 32-64 µg/ml), Klebsiella aerogenes (MIC: 16-32 µg/ml), Citrobacter freundii (MIC: >128 µg/ml), Escherichia coli (MIC: 4-8 µg/ml), Escherichia coli (MIC: 4-8 µg/ml), Enterococcus faecium (MIC: 2-8 µg/ml), Streptococcus pneumoniae (MIC: 16-32 µg/ml), Staphylococcus haemolyticus (MIC: 8-16 µg/ml), Staphylococcus epidermidis (MIC: 16-32 µg/ml), Staphylococcus aureus (MIC: 4-8 µg/ml), Staphylococcus aureus (MIC: 4-16 µg/ml), Human lung carcinoma A549"	QWGRRCCGWGPGRRYCRRWC	20	"Experimental evidence at protein level"	2542.97	2541.15	10.66	--NA--	"The N-terminal glutamine is believed to be cyclized (i.e., pyroglutamate, XXQ). It contains two disulfide bonds (6-16 and 7-20). A recombinant form is active against clinical multiresistant isolates including MRSA (S. aureus) and extended spectrum ±-lactamases-producing E. coli ( Fan X et al., 2013). Activity and sequence relationship was investigated (Peptides. 2005 Jul;26(7):1113-9). Updated 5/30/2013; Synthesis Type : Ribosomal|shows 8% Inhibition against Human lung carcinoma A549 at 200 ¼g/ml, Antimicrobial assays shows that it could efficiently target clinical multiresistant isolates including methicillin-resistant Staphylococcus aureus and extended-spectrum ±-lactamase-producing E. Coli."